NEW HAVEN, Conn. — February 12, 2026 — Leads & Copy — Arvinas, Inc. has appointed Randy Teel, Ph.D., as President and Chief Executive Officer (CEO) and a member of the Company’s Board of Directors, effective today. Arvinas is a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation.
Dr. Teel previously served as Arvinas’ Chief Business Officer (CBO). He succeeds John Houston, Ph.D., who is retiring as President, Chief Executive Officer, and Chair of Arvinas’ Board. Houston will remain on the Board and has a consulting agreement with Arvinas to provide advisory services. Briggs Morrison, M.D., has been elected Chair of the Arvinas Board, also effective today.
Morrison said the board is pleased to announce Randy as President and Chief Executive Officer, after a comprehensive search. He added that Teel brings a strategic vision, a deep understanding of the company’s scientific and operational foundation, and an ability to understand and address the priorities of multiple stakeholders. Morrison also thanked Houston for his leadership, vision, and contributions over the past nine years.
Dr. Teel joined Arvinas in 2018 and has 20 years of biopharmaceutical industry experience. He played a role in Arvinas’ 2018 initial public offering (IPO) and the company’s transition to a public, clinical-stage biotechnology company. As CBO, Dr. Teel was responsible for corporate strategy, business development, investor relations, and communications, as well as leadership roles driving strategic initiatives and long-range planning. Earlier at Arvinas, Dr. Teel led commercial development and served as Arvinas’ interim Chief Financial Officer and Treasurer.
Dr. Teel formerly served as Vice President and Head of Strategy at Alexion Pharmaceuticals, where he led long-range planning and partnered with R&D and commercial teams to shape inline and lifecycle management strategies. Prior to Alexion, Dr. Teel was an Associate Partner at McKinsey & Company, where he advised biopharmaceutical clients on issues in commercial, medical, and development. He holds a B.Sc. in Biology from Gonzaga University and a Ph.D. in Immunobiology from Yale University.
Dr. Teel said he is honored to step into this role at a pivotal moment for Arvinas. He added that the company is directing its attention to earlier stage clinical programs and their potential to transform treatment paradigms for patients with serious diseases. Teel also said that under Houston’s leadership, they have created the leading PROTAC platform in the industry, generating high-quality candidates and advancing programs with the potential to become transformative treatments for patients.
During his time as President and CEO, Dr. Houston advanced Arvinas through milestones, including progressing multiple investigational programs into clinical development, reporting the first positive pivotal results for a PROTAC degrader, and demonstrating central nervous system pharmacodynamic activity for an orally administered PROTAC. Dr. Houston led Arvinas to its 2018 IPO and raised over $2 billion through private funding, partnerships and strategic collaborations, and follow-on financings.
Houston said he is proud of what has been accomplished and confident that Teel will lead Arvinas to new levels of innovation and impact. He said the team is well-positioned under Teel’s leadership as they approach milestones later this year, including clinical data from LRRK2, BCL6 and KRAS G12D degraders. He also said that he looks forward to supporting Teel and the entire organization as Arvinas continues to push the boundaries of what’s possible for patients.
Arvinas is dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC protein degrader platform, Arvinas is developing protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Arvinas is progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut.
Source: Arvinas
